Analyzing NIH Funding Patterns
|
|
- Clarissa Crawford
- 5 years ago
- Views:
Transcription
1 Analyzing NIH Funding Patterns with Statistical Text Analysis Margaret Blume-Kohout New Mexico Consor>um Jihyun Park Eric Nalisnick Padhraic Smyth Dept. Of Computer Science University Of California, Irvine Ralf Krestel Web Science Research Group Hasso-PlaGner-Ins>tut
2 Measuring the Impact of NIH(National Institute of Health) Funding 2 NIH invests over $30 billion each year Can we gain insight into this process using text and metadata? Our approach is to use sta>s>cal topic modeling We used grants data from NCI (Na>onal Cancer Ins>tute) 6 NCI FUNDING AMOUNT 11 NCI FUNDED GRANTS BILLIONS (US DOLLARS) NUMBER OF GRANTS (THOUSANDS) YEAR ARRA Funded YEAR
3 Overview 3 NCI Data PROJECT ID GRANT ABSTRACT GENETICS... RCDC Labels For each grant FUNDING YEAR Text ClassificaCon Techniques HUMAN GENOME 0.8 BIOENGINEERING 0.7 NANO TECHNOLOGY 0.2 Probability of each label 0 being 0.25associated 0.5 with 0.75 the 1grant Funding paaerns over Cme for each area Funding + Year informacon
4 NCI (National Cancer Institute) Data 4 Grant abstracts from 1994 through 2013 Text Processing BOW representa>on Removed 500 common stopwords Extracted noun-phrase terms using a NLP parser BOW Data Total 149,901 documents Number of documents with labels (training data) : 31,628 (2008~2011) Number of documents without labels : 118,273 Size of vocabulary (W) : 29,713
5 LDA: Topics are Represented as Distributions over Words 5 Figures from Mark Steyvers Terrorism Wall Street Firms Stock Market Bankruptcy SEPT_11 WAR SECURITY IRAQ TERRORISM NATION KILLED AFGHANISTAN ATTACKS OSAMA_BIN_LADEN WALL_STREET ANALYSTS INVESTORS FIRM GOLDMAN_SACHS FIRMS INVESTMENT MERRILL_LYNCH COMPANIES SECURITIES WEEK DOW_JONES POINTS 10_YR_TREASURY_YIELD PERCENT CLOSE NASDAQ_COMPOSITE STANDARD_POOR CHANGE FRIDAY BANKRUPTCY CREDITORS BANKRUPTCY_PROTECTION ASSETS COMPANY FILED BANKRUPTCY_FILING ENRON BANKRUPTCY_COURT KMART
6 LDA: Documents are Represented as Combinations of Topics 6 Figures from Mark Steyvers Terrorism Wall Street Firms Stock Market Bankruptcy SEPT_11 WAR SECURITY IRAQ TERRORISM NATION KILLED AFGHANISTAN ATTACKS OSAMA_BIN_LADEN WALL_STREET ANALYSTS INVESTORS FIRM GOLDMAN_SACHS FIRMS INVESTMENT MERRILL_LYNCH COMPANIES SECURITIES WEEK DOW_JONES POINTS 10_YR_TREASURY_YIELD PERCENT CLOSE NASDAQ_COMPOSITE STANDARD_POOR CHANGE FRIDAY BANKRUPTCY CREDITORS BANKRUPTCY_PROTECTION ASSETS COMPANY FILED BANKRUPTCY_FILING ENRON BANKRUPTCY_COURT KMART 70% 30% Document 1 50% 50% 90% Document 2 Document 3
7 LDA (Latent Dirichlet Allocation) 7 W T W T D D
8 LDA (Latent Dirichlet Allocation) 8 Topic Models as Factor Analysis for Count Data W T W T D D T topic weights for each document topic-word probability distribucon
9 NIH Data Representation for L-LDA 9 Words or Terms brain lung_cancer women obesity children mice experiment hbv quality glioma researcher doc doc2 1 1 doc3 2 1 Documents doc doc5 1 1 doc6 2 doc7 1 1 doc8 2 1 doc doc10 2
10 NIH Data Representation for L-LDA 10 Words or Terms Codes or Labels brain lung_cancer women obesity children mice experiment hbv quality glioma researcher brain cancer breast cancer kidney disease lung cancer mind and body doc doc doc Documents doc doc5 1 1 doc6 2 doc doc8 2 1 doc doc
11 NIH Data Representation for L-LDA 11 Words or Terms Codes or Labels brain lung_cancer women obesity children mice experiment hbv quality glioma researcher Documents brain cancer breast cancer kidney disease lung cancer mind and body Background 1 Background 2 doc doc2 1 1 doc3 2 1 doc doc5 1 1 doc6 2 doc7 1 1 doc8 2 1 doc doc
12 Examples of Topics from NCI Abstracts (5 out of 98) 12 Brain Cancer glioma brain tumor gbm malignant glioma glioblastoma brain Breast Cancer breast cancer women breast cancer cell breast breast cancer pacent brca1 Kidney Disease rcc kidney cancer renal cell carcinoma vhl renal cancer pvhl Background 1 program trainee university training candidate field Background 7 model mice work experiment human mouse model 88 Topics from RCDC labels 10 Background topics
13 Evaluation 13 Grants with RCDC labels (31,628 documents) terms TRAIN 90 % 28K docs TEST 10 % 3K docs p(code doc) AUC R-Precision p(code doc) i p(code word i,doc) Sampling probabili>es were averaged over the words in a document to calculate AUC and R-precision scores
14 Logistic Regression Classifier 14 p(code = 1 doc) p(code = 2 doc) 88 logiscc regression classifiers trained to produce calibrated probabilices using training data p(code = k doc) p(code = 87 doc) p(code = 88 doc) LogisCc Regression Classifier p LR (code = k d) L-LDA TOPIC PROBABILITY CALIBRATED TOPIC PROBABILITY
15 Evaluation Result 15 p(c d) p LR (c d) L-LDA L-LDA + LogisCc Regression AUC R-Precision
16 Analyzing Funding Patterns over Time 16 Frac>onally assign the funds in direct propor>on to the probabili>es from the logis>c regression classifiers p LR (code doc) w cd = k p LR (c d) p k (c = k d) c = 1,2,...88 F c y = d:y d =y w cd x d w cd x d y d y F c : weight for the category c for document d : amount of funding for document d (considered infla>on) : year when document d was funded : total es>mated amount of funding for category c in year y
17 Nanotechnology Networking-and-Information-Technology-RandD Human-Genome Obesity FUNDING PERCENTAGE YEAR Es>mated percentage of funding allocated to 4 general RCDC categories
18 Lung-Cancer Liver-Cancer Brain-Cancer Infectious-Diseases 1.4 FUNDING PERCENTAGE YEAR Es>mated percentage of funding allocated to 4 specific RCDC disease categories
19 19 7 Breast-Cancer Translational-Research Epidemiology-And-Longitudinal-Studies 6 FUNDING PERCENTAGE YEAR
20 Genetics Biotechnology Breast-Cancer Obesity Sleep-Research FUNDING PERCENTAGE YEAR
21 Conclusions 21 Summary Labeled topic modeling and logis>c classifiers can be combined to analyze NIH grant funding data Sta>s>cal topic modeling allows linking of text with metadata in a quan>fiable manner Future Work Jointly analyze grants and scien>fic ar>cles related to the grants (ongoing) Broader analysis of the economic and policy implica>ons Improvements on topic model How to best calibrate Selec>ng the right Hyper parameters Methods such as using seed words
22 22 THANK YOU
23 23 BACKUP SLIDES
24 NCI (National Cancer Institute) Data 24 PROJECT ID GRANT ABSTRACT NCI Data... RCDC Labels FUNDING YEAR # number of tokens Number of tokens in a document number of labels per document Number of labels in a document
25 Examples of Topics from NCI Abstracts (5 out of 88) 25 Brain Cancer glioma brain tumor gbm malignant glioma glioblastoma brain Breast Cancer breast cancer women breast cancer cell breast breast cancer pacent brca1 Kidney Disease rcc kidney cancer renal cell carcinoma vhl renal cancer pvhl HepaCCs hcv hbv liver cancer hepaccs virus hbv infeccon hbv replicacon Lung Cancer gliomalung cancer nsclc lung leading cause cancer death egfr
26 Labeled-LDA for NIC Grants Topics (RCDC Codes) 10 Background Topics Hyper parameters Dirichlet prior for word-topic distribu>on = 0.01 β w Dirichlet prior for doc-topic distribu>on Used propor>onal alphas 88 α c = 5 α b = 1 c=1 B b
27 27
28 Analyzing Funding Patterns over Time 28 Frac>onally assign the funds in direct propor>on to the probability p l (c d) w cd = k p k (c = k d) c = 1,2,...88 F c y = d:y d =y w cd x d
29 NCI (National Cancer Institute) Data ,901 grants in total for FY1994 ~ FY2013 Number of grants with labels : 31,628 (2008~2011) Number of grants without labels : 118,273 W Size of vocabulary (W) : 29, D
Extracting Semantic Themes with Topic Models
Extracting Semantic Themes with Topic Models Mark Steyvers Department of Cognitive Sciences University of California, Irvine Collaborators: Tom Griffiths, UC Berkeley Padhraic Smyth, UC Irvine Research
More informationPlanning, Priority Setting, and Budget Development for NIH AIDS Research
Planning, Priority Setting, and Budget Development for NIH AIDS Research Robert W. Eisinger, Ph.D. Office of AIDS Research s of Health Focus of Presentation Overview of OAR Priority Setting Process Budget
More informationNektar Investor & Analyst Call. Nektar & z Bristol-Myers Squibb Collaboration. February 14, 2018
Nektar Investor & Analyst Call Nektar & z Bristol-Myers Squibb Collaboration February 14, 2018 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the
More informationMathematical Modeling of PDGF-Driven Glioblastoma Reveals Optimized Radiation Dosing Schedules
Mathematical Modeling of PDGF-Driven Glioblastoma Reveals Optimized Radiation Dosing Schedules Kevin Leder, Ken Pittner, Quincey LaPlant, Dolores Hambardzumyan, Brian D. Ross, Timothy A. Chan, Eric C.
More informationCorporate Presentation March 2016
Corporate Presentation March 2016 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationArgos Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results
March 27, 2014 Argos Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results - AGS-003 Phase 3 ADAPT Trial on Track to Complete Enrollment This Year - - AGS-004-Induced Immune Responses
More informationmicrorna Therapeutics Heading Towards the Clinic
GENReports: Market & Tech Analysis microrna Therapeutics Heading Towards the Clinic > Enal Razvi, Ph.D. Biotechnology Analyst, Managing Director SELECTBIO US enal@selectbio.us Topic Introduction and Scope
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationPREVENTION FOR A HEALTHIER AMERICA: Investments in Disease Prevention Yield Significant Savings, Stronger Communities
PREVENTION FOR A HEALTHIER AMERICA: Investments in Disease Prevention Yield Significant Savings, Stronger Communities Jeffrey Levi, PhD Executive Director, Trust for America s Health Barbara A. Ormond,
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationUroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011
Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011 Forward Looking Statement This presentation includes forward-looking statements, including financial projections, relating
More informationFounded in 2016 to develop life-changing therapies against debilitating aggressive cancers that have limited treatment options
Founded in 2016 to develop life-changing therapies against debilitating aggressive cancers that have limited treatment options Integrated platform technology for discovery of novel molecular targets and
More informationDelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75)
Equity Healthcare / Biotechnology Update (December 3, 2015) DelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75) DelMar Pharmaceuticals, Inc. ( DelMar, OTCQX: DMPI) is a clinical stage biotechnology
More informationVICAL INC FORM 8-K. (Current report filing) Filed 11/02/06 for the Period Ending 11/02/06
VICAL INC FORM 8-K (Current report filing) Filed 11/02/06 for the Period Ending 11/02/06 Address 10390 PACIFIC CENTER COURT. SAN DIEGO, CA 92121-4340 Telephone 858-646-1100 CIK 0000819050 Symbol VICL SIC
More informationInference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics, 2010
Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics, 2010 C.J.Vaske et al. May 22, 2013 Presented by: Rami Eitan Complex Genomic
More informationAGM Presentation For the year to 30 September February 2016
AGM Presentation For the year to 30 September 2015 25 February 2016 11 Forward Looking Statements This presentation includes forward-looking statements. These forward-looking statements involve known and
More informationNew Anticancer Agents Targeting the Tumor-Specific Microenvironment (OTT ID 1277)
New Anticancer Agents Targeting the Tumor-Specific Microenvironment (OTT ID 1277) Inventor: Xiaohua Peng, Associate Professor, Department of Chemistry and Biochemistry UW-Milwaukee For further information
More informationImage of Ebola viruses exiting host cells HUMAN VIRUSES & THE LIMITATION OF ANTIVIRAL DRUG AGENTS
Image of Ebola viruses exiting host cells HUMAN VIRUSES & THE LIMITATION OF ANTIVIRAL DRUG AGENTS APRIL 2017 Infectious viruses are a global health threat Since the approval of the first antiviral drug
More informationImage of Ebola viruses exiting host cells HUMAN VIRUSES & THE LIMITATION OF ANTIVIRAL DRUG AGENTS
Image of Ebola viruses exiting host cells HUMAN VIRUSES & THE LIMITATION OF ANTIVIRAL DRUG AGENTS MAY 2017 1 Infectious viral pathogens are a significant global health threat to mankind 2 Since the approval
More informationSmall-Cap Research. Delmar Pharma (DMPI-OTCQB)
Small-Cap Research February 24, 2015 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Delmar Pharma (DMPI-OTCQB) DMPI: Ready to advance VAL-083 to pivotal
More informationSmall-Cap Research. Diffusion Pharmaceuticals Inc. (DFFN-NASDAQ) DFFN: FDA Gives Final Guidance for Phase 3 Protocol for TSC in Inoperable GBM OUTLOOK
Small-Cap Research November 16, 2017 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Diffusion Pharmaceuticals Inc. (DFFN-NASDAQ) DFFN: FDA Gives Final
More informationCenters for Disease Control and Prevention (CDC) Coalition C/o American Public Health Association 800 I Street NW Washington, DC,
Centers for Disease Control and Prevention (CDC) Coalition C/o American Public Health Association 800 I Street NW Washington, DC, 20001 202-777-2514 Donald Hoppert, Director of Government Relations, American
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More informationCommon Data Elements: Making the Mass of NIH Measures More Useful
Common Data Elements WG Common Data Elements: Making the Mass of NIH Measures More Useful Jerry Sheehan Assistant Director for Policy Development Na?onal Library of Medicine Gene/c Alliance Webinar Series
More informationInnovative Risk and Quality Solutions for Value-Based Care. Company Overview
Innovative Risk and Quality Solutions for Value-Based Care Company Overview Meet Talix Talix provides risk and quality solutions to help providers, payers and accountable care organizations address the
More informationSub-Topic Classification of HIV related Opportunistic Infections. Miguel Anderson and Joseph Fonseca
Sub-Topic Classification of HIV related Opportunistic Infections Miguel Anderson and Joseph Fonseca Introduction Image collected from the CDC https://www.cdc.gov/hiv/basics/statistics.html Background Info
More information2Q 2017 Ceramic Tile Industry Update
2Q 2017 Ceramic Tile Industry Update U.S. Tile Consumption Overview: by Andrew Whitmire At the midway point of 2017, the U.S. ceramic tile market appears headed for its eighth consecutive year of growth.
More informationByers Eye Horngren Family Center, Department of Ophthalmology, Stanford University School of Medicine, Palo Alto, California
The Importance of Keeping a Broad Differen6al In Re6na Clinic: The Spectrum of Disease Seen By Re6nal Specialists in a Ter6ary Outpa6ent Clinic Se@ng Darius M. Moshfeghi 1, MD, Suzann Pershing, MD 1, Natalia
More informationReview of Half Year 2010
Aiming i to Become a Top Japanese Pharmaceutical Company Review of Half Year 2010 CHUGAI PHARMACEUTICAL CO., LTD. President and CEO Osamu Nagayama July 22/23, 2010 Forward-Looking Statementst t Aiming
More informationSmall-Cap Research. Delmar Pharma (DMPI-NASDAQ) DMPI: Zacks Company Report OUTLOOK
Small-Cap Research May 25, 2017 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Delmar Pharma (DMPI-NASDAQ) DMPI: Zacks Company Report DMPI: A New Phase
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer January 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More informationNIDA Par9cipa9on in Major NIH Pain Consor9um Ini9a9ves
NIDA Par9cipa9on in Major NIH Pain Consor9um Ini9a9ves David A. Thomas, Ph.D. Deputy Director, Division of Clinical Neuroscience and Behavioral Research, Na9onal Ins9tute on Drug Abuse NIH Pain Consor9um
More informationMOLOGEN AG. Our research for you. Annual Results Analysts Call March 21, 2013
Our research for you. Annual Results 2012 Analysts Call March 21, 2013 Disclaimer Certain statements in this communication contain formulations or terms referring to the future or future developments,
More informationINTERNATIONAL MASTERCLASS ON LIVER DISEASE IN HIV VILNIUS, LITHUANIA 18 SEPTEMBER 2019 (TBC) REQUEST FOR SUPPORT.
INTERNATIONAL MASTERCLASS ON LIVER DISEASE IN HIV VILNIUS, LITHUANIA 18 SEPTEMBER 2019 (TBC) REQUEST FOR SUPPORT INTRODUCTION Liver disease in the setting of HIV is increasingly presenting a major concern
More informationAVEO and Astellas Report Final Overall Survival Results from TIVO-1
AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,
More informationIMPACT. Koen Verhoef, director Tech Transfer office Netherlands Cancer Ins:tute, Amsterdam
IMPACT Koen Verhoef, director Tech Transfer office Netherlands Cancer Ins:tute, Amsterdam Structure of this presenta:on - What is Impact? - How is it measured? - Inside academia - Outside - Increasing
More informationEmerging gene)cs in schizophrenia: Real challenges for crea)ng animal models
Emerging gene)cs in schizophrenia: Real challenges for crea)ng animal models Steven A McCarroll, PhD Stanley Center for Psychiatric Research, Broad Ins7tute Department of Gene7cs, Harvard Medical School
More informationAVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer
FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated
More informationNew Developments in Cancer Treatment. Dulcinea Quintana, MD
New Developments in Cancer Treatment Dulcinea Quintana, MD Mortality Rates Goals of treatment 1 Cure Goal of treatment 2 Prolong life Goals of treatment 3 Improve Quality of Life Goals of treatment 4
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationCell Therapy. Cytori Corporate Presentation January 2012
Cytori Corporate Presentation January 2012 Safe Harbor This presentation may contain certain forward-looking statements. All statements, other than statements of historical fact, that address activities,
More informationInvestor presentation. Bioshares Biotech Summit July 2017
Investor presentation Bioshares Biotech Summit 2017 22 July 2017 1 Disclaimer Some of the information in this presentation may refer to Dimerix Limited ( Dimerix or the Company ) based on information available
More informationMaria Halasz CEO
Australian biotechnology company listed on the ASX (CDY.AX) Midkine company owns novel therapeutic and diagnostic target Extensive scientific validation including 550+ publications Multiple revenue source
More informationOn behalf of the Infectious Diseases Society of America (IDSA), I am pleased to provide
Transmitted by Jonathan Nurse, Director of Government Relations, IDSA The Infectious Diseases Society of America s (IDSA) Fiscal Year 2015 Funding Statement Submitted to the House Appropriations Subcommittee
More informationscr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL (MBVX - Nasdaq) OUTLOOK ZACKS ESTIMATES
Small-Cap Research August 26, 2016 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 MabVax Therapeutics Holdings, Inc. MBVX: Uplist to Nasdaq
More informationUKParl: A Data Set for Topic Detection with Semantically Annotated Text
UKParl: A Data Set for Topic Detection with Semantically Annotated Text Federico Nanni, Mahmoud Osman, Yi-Ru Cheng, Simone Paolo Ponzetto and Laura Dietz My Research Post-Doc in computational social science
More informationDS-8201 Strategic Collaboration
DS-8201 Strategic Collaboration DAIICHI SANKYO CO., LTD George Nakayama Chairman and CEO March 29, 2019 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections
More informationCatalyzing the Next Generation of Cancer Technologies
Catalyzing the Next Generation of Cancer Technologies Presentation to the IOM Workshop on the Cures Acceleration Network June 4, 2012 Michael Weingarten Director, NCI SBIR Development Center Today s Presentation
More informationThe Mortality Effects of Re3rement: Evidence from Social Security Eligibility at Age 62
The Mortality Effects of Re3rement: Evidence from Social Security Eligibility at Age 62 Maria D. Fitzpatrick Cornell University & NBER Timothy J. Moore George Washington University & NBER Funded by grants
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer September 2013 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More informationVAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018
VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients September 2018 Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may
More informationRNAi in HBV, the next backbone therapy for use in combinations? Bruce D. Given, MD COO, Arrowhead Pharmaceuticals L.I.F.E.R.
RNAi in HBV, the next backbone therapy for use in combinations? Bruce D. Given, MD COO, Arrowhead Pharmaceuticals L.I.F.E.R. October 20, 2017 Safe Harbor Statement This presentation contains forward-looking
More informationPioneering vaccines that transform lives.
Pioneering vaccines that transform lives. Immunomic Therapeutics, Inc. LAMP-Vax for Glioblastoma: CMV-LAMP-Vax Executive Summary Executive Summary pp65-lamp-vax First Line Therapy for Glioblastoma Multiforme
More informationPandemic Influenza: Appropriations for Public Health Preparedness and Response
Order Code RS22576 January 23, 2007 Pandemic Influenza: Appropriations for Public Health Preparedness and Response Summary Sarah A. Lister Specialist in Public Health and Epidemiology Domestic Social Policy
More informationAn Intelligent Writing Assistant Module for Narrative Clinical Records based on Named Entity Recognition and Similarity Computation
An Intelligent Writing Assistant Module for Narrative Clinical Records based on Named Entity Recognition and Similarity Computation 1,2,3 EMR and Intelligent Expert System Engineering Research Center of
More informationHEALTH MATTERS, INC. SUMMARY OF PROJECTS AND KEY ACCOMPLISHMENTS TO 2016
Selected 2016 Highlights Epidemiologic research on chronic kidney disease and fistula patency, solid and hematologic malignancies Health economics and outcomes research on beta3-agonist treatment for overactive
More informationMachine-Learning on Prediction of Inherited Genomic Susceptibility for 20 Major Cancers
Machine-Learning on Prediction of Inherited Genomic Susceptibility for 20 Major Cancers Sung-Hou Kim University of California Berkeley, CA Global Bio Conference 2017 MFDS, Seoul, Korea June 28, 2017 Cancer
More informationHepatitis B. HBV Cure: Insights for the Biotechnology and the Research Analyst Community November 11, Lalo Flores, PhD Global Head HBV R&D
Hepatitis B HBV Cure: Insights for the Biotechnology and the Research Analyst Community November 11, 2016 Lalo Flores, PhD Global Head HBV R&D Infectious Diseases Diseases Infectious 11 Janssen s Vision
More informationAvenue Therapeutics, Inc. September 2016
Avenue Therapeutics, Inc. September 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the
More informationCasual Methods in the Service of Good Epidemiological Practice: A Roadmap
University of California, Berkeley From the SelectedWorks of Maya Petersen 2013 Casual Methods in the Service of Good Epidemiological Practice: A Roadmap Maya Petersen, University of California, Berkeley
More informationForward Looking Statements
Slide title Forward Looking Statements This presentation may contain forward looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited
More informationJP Morgan Healthcare Conference
JP Morgan Healthcare Conference Lamberto Andreotti Chief Executive Officer January 14, 2014 Forward-Looking Information During this meeting, we will make statements about the Company s future plans and
More informationBIOTRON LIMITED (ASX:BIT) Broker Meet Biotech August 2018
BIOTRON LIMITED (ASX:BIT) Broker Meet Biotech August 2018 Dr Michelle Miller Managing Director +61 412 313329 mmiller@biotron.com.au www.biotron.com.au Forward Looking Statements This presenta8on may contain
More informationExploring Trends of Cancer Research Based on Topic Model
Exploring Trends of Cancer Research Based on Topic Model Mingliang Cui, Yanchun Liang *, Yuping Li, Renchu Guan * College of Computer Science and Technology, Jilin University, Changchun, 130012, China
More informationSustain and Seize Cancer Research Opportunities
One Voice Against Cancer (OVAC) appreciates the opportunity to submit written comments for the record regarding funding for cancer programs for research, prevention, detection, and treatment as well as
More informationSociety for Prevention Research 2018 Call for Papers Author Abstract Submission Questions. Research Foci
Society for Prevention Research 2018 Call for Papers Author Abstract Submission Questions Research Foci Please select your Research Foci. (Select all that apply) Academic Achievement ADHD Addiction Aging
More informationTHE UC SANTA CRUZ GENOMICS INSTITUTE. David Haussler Distinguished Professor, Biomolecular Engineering Scientific Director
THE UC SANTA CRUZ GENOMICS INSTITUTE David Haussler Distinguished Professor, Biomolecular Engineering Scientific Director April 8, 2015 OUR MISSION Unlocking the world s genomic data to accelerate medical
More informationPaul Murray University of Birmingham
Paul Murray University of Birmingham College of Medical and Dental Sciences The people of the Midlands have every reason to be supremely proud of this great centre of healing, of teaching and of research.
More informationDo Firms Underinvest In Long-Term Research? Evidence From Cancer Clinical Trials
SIEPR policy brief Stanford University May 2014 Stanford Institute for Economic Policy Research on the web: http://siepr.stanford.edu Do Firms Underinvest In Long-Term Research? Evidence From Cancer Clinical
More informationHealth Systems Adoption of Personalized Medicine: Promise and Obstacles. Scott Ramsey Fred Hutchinson Cancer Research Center Seattle, WA
Health Systems Adoption of Personalized Medicine: Promise and Obstacles Scott Ramsey Fred Hutchinson Cancer Research Center Seattle, WA Cancer Pharmaceutical Pricing Bach P. NEJM 2009;360:626 Opportunities
More informationAVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC
FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year
More informationBiomarker as essential part of clinical development. PhUSE 2014, London, Renuka Chinthapally, Cytel
Biomarker as essential part of clinical development PhUSE 2014, London, Renuka Chinthapally, Cytel 1 Disclaimer Any comments or statements made here are solely those of the author and do not necessarily
More informationMedia Release. Basel, 18 February 2017
Media Release Basel, 18 February 2017 Phase II study supports potential for Roche s TECENTRIQ (atezolizumab) plus Avastin (bevacizumab) for people with locally advanced or metastatic renal cell carcinoma
More informationGenomics in the Kidney Clinic
Genomics in the Kidney Clinic Translation, Implementation and Challenges Dr Andrew Mallett Nephrologist, RBWH & MNHHS National Director, KidGen AGHA Renal Genetics Flagship Why Kidneys? Frequency, Outcomes
More informationCHECK AGAINST DELIVERY:
Beijing launch of Preventing Chronic Disease: a vital investment Speech by Dr Catherine Le Galès-Camus, Assistant Director-General, World Health Organization, Non-communicable Diseases and Mental Health
More informationAvenue Therapeutics, Inc. August 2016
Avenue Therapeutics, Inc. August 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the safe
More informationExperimenting with Drugs (and Topic Models) Michael Paul and Mark Dredze Johns Hopkins University
Experimenting with Drugs (and Topic Models) Michael Paul and Mark Dredze Johns Hopkins University Online Drug Communities Drugs- Forum.com Drugs- forum is an information hub of high- standards and a platform
More informationCrisis Investing: Profits From a Diabetes Drug About to Get Approved Crisis Investing: Profits From a Diabetes Drug About to Get Approved
Crisis Investing: Profits From a Diabetes Drug About to Get Approved A Special Research Report from Bret Jensen's Biotech Gems Lexicon Pharmaceuticals (Nasdaq: LXRX): tackling one of America s biggest
More informationMAGFORCE AG FIGHTING CANCER WITH NANO MEDICINE
MAGFORCE AG FIGHTING CANCER WITH NANO MEDICINE 2014, Berlin, Germany 2 EXECUTIVE SUMMARY Company Profile Headquartered in Berlin, Germany Current Management Team: B. Lipps, H. Tawfik, C. von Volkmann Frankfurt
More informationKnowledge networks of biological and medical data An exhaustive and flexible solution to model life sciences domains
Knowledge networks of biological and medical data An exhaustive and flexible solution to model life sciences domains Dr. Sascha Losko, Dr. Karsten Wenger, Dr. Wenzel Kalus, Dr. Andrea Ramge, Dr. Jens Wiehler,
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer June 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results may
More informationAssociation of American Cancer Institutes
Association of American Cancer Institutes Statement by the Association of American Cancer Institutes on Fiscal Year (FY) 2016 Appropriations for the Department of Health and Human Services Subcommittee
More informationPrecision Therapeutics For Hard-To-Treat Cancers
Precision Therapeutics For Hard-To-Treat Cancers George O. Elston, CEO Life Sciences Summit November 2, 2017 1 About Us Precision therapeutics addressing significant unmet medical needs in hard-to-treat
More informationLetter from the CEO IN THIS ISSUE. Harnessing the body s own defence systems to combat cancer LETTER FROM THE CEO
INVESTOR NEWSLETTER MAY 2018 Harnessing the body s own defence systems to combat cancer Letter from the CEO Dear Shareholders, Since the company s last newsletter Patrys has made significant headway on
More informationSECTION 2: ABOUT THE LIVER
SECTION 2: ABOUT THE LIVER The liver is an organ in the body that has many criccal funccons When the liver becomes very damaged (such as by chronic viral hepaccs), it cannot work properly Serious liver
More informationCancer 101 Spring Family Cancer Retreat 4/18/15. Amish Shah, M.D. New Mexico Cancer Center
Cancer 101 Spring Family Cancer Retreat 4/18/15 Amish Shah, M.D. New Mexico Cancer Center Topics to cover What is Cancer? Screening Diagnosis/Staging Treatment Basics Clinical Trials Surveillance What
More informationCowen Health Care Conference
Cowen Health Care Conference Dr. Fouad Namouni Head of Medical March 7, 2016 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer March 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn's actual results may
More informationMolecular Imaging in the Development of Cancer Therapeutics. Johannes Czernin
Molecular Imaging in the Development of Cancer Therapeutics Johannes Czernin Ahmanson Biological Imaging Division University of California Los Angeles Cancer Statistics Cancer Type 5-year Survival Rate
More informationChapter III: Summary of Data for Specific Cancers
Chapter III: Summary of Data for Specific Cancers [This page left intentionally blank.] Chapter III Chapter III: Summary of Data for Specific Cancers This chapter provides detailed information on the most
More informationNIAAA UPDATE. Daniel Falk, Ph.D. Brett Hagman, Ph.D. Robert Huebner, Ph.D. Division of Treatment and Recovery Research, NIAAA
NIAAA UPDATE Daniel Falk, Ph.D. Brett Hagman, Ph.D. Robert Huebner, Ph.D. Division of Treatment and Recovery Research, NIAAA 11 th Annual RSA Satellite Session on Mechanisms of Behavior Change: San Antonio,
More informationSubmitted electronically to:
Submitted electronically to: ODOARRFI19@nih.gov Maureen Goodenow, PhD Associate Director of AIDS Research, NIH Director, Office of AIDS Research (OAR) National Institutes of Health 5601 Fishers Lane. Room
More informationLocal EBQ Course - PERU Epidemiology, Biostatistics & Qualitative Research Methods
, Biostatistics & 20 places available Iquitos, Peru Apply now for this 3-week course! Applica7on procedure and criteria for academic eligibility and funding can be found on www.uantwerp.be/ebq-peru Deadline
More informationPRESENTATION TO INVESTORS. I attach a PowerPoint presentation as presented by Biotron Limited's CEO, Dr Michelle Miller, to investors today.
Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au 11 November 2010 The Manager Companies ASX Limited
More informationCEL-SCI Corporation. NYSE American: CVM
CEL-SCI Corporation NYSE American: CVM Geert Kersten Chief Executive Officer 8229 Boone Boulevard, Suite 802 Vienna, VA 22182, USA Phone: (703) 506-9460 Forward Looking Statements This presentation includes
More informationRenal Cell Carcinoma: Research And Treatments
Renal Cell Carcinoma: Research And Treatments Renal Cell Carcinoma - Medscape - therapies for treatment of advanced renal cell carcinoma? for Research and Treatment of Cancer of renal cell carcinoma. Renal
More informationRepresentation pathways for marginalised women survivors of conflict Terms of Reference
Representation pathways for marginalised women survivors of conflict Terms of Reference Women for Women International (WfWI) is looking for a UK-based, experienced, feminist consultant to deliver a desk-based
More informationPfizer Independent Grants for Learning & Change Track 2- Annual Meetings: Submission Deadlines, Areas of Interest & Educational Goals
In order to submit a request for general meeting support through Track 2- Annual Meetings the answer to the following questions must be Yes : Does the activity align with Pfizer s areas of interest? (listed
More informationOn behalf of the Infectious Diseases Society of America (IDSA), I offer testimony in
Testimony of the Infectious Diseases Society of America (IDSA) on the Fiscal Year 2018 Department of Health and Human Services Budget Prepared for the U.S. House of Representatives Subcommittee on Labor-HHS-Education
More informationMERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018
MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward
More information